News >

Frontline Setting in mRCC Continues to Evolve With Combo Regimens

Caroline Seymour
Published: Tuesday, Nov 12, 2019

Thai H. Ho, MD, PhD, a consultant in the division of Hematology/Oncology, Department of Internal Medicine, and assistant professor of medicine, at Mayo Clinic

Thai H. Ho, MD, PhD

The FDA approvals of dual immunotherapy and TKI/immunotherapy combinations for use in patients with newly diagnosed, metastatic renal cell carcinoma (mRCC) have signaled a shift away from TKI monotherapy in the frontline setting, according to Thai H. Ho, MD, PhD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication